Can Mycoplasma pneumoniae infection cause persistent antibodies and inflammatory complications?

Mycoplasma pneumoniae is recognized for its capacity to cause prolonged systemic and extrapulmonary pathology beyond acute respiratory disease, presenting unique diagnostic and clinical challenges.

Immunological persistence and antibody kinetics

• Mycoplasma pneumoniae can establish chronic respiratory colonization by invading non-phagocytic host cells and utilizing antigenic variation to evade host defenses.
• This persistence drives prolonged humoral responses: pathogen-specific IgM antibodies frequently remain detectable for 3 to 6 months (and up to a year), while IgG levels can persist for 2 to 9 years post-infection. This makes single serological titers insufficient for distinguishing acute from historical exposure.

Systemic activation and neurovascular complications

• Infection triggers systemic inflammatory cascades characterized by elevated pro-inflammatory cytokines (TNF-α, IL-6, IL-8) and endothelial activation.
• Neurologic complications, such as post-infectious encephalitis and demyelinating syndromes, are driven by molecular mimicry. The pathogen induces cross-reactive anti-galactocerebroside (anti-GalC) antibodies that target host myelin glycolipids.
• Vascular inflammatory complications, including ischemic stroke and thrombosis, occur due to local vasculitis and a systemic hypercoagulable state marked by elevated D-dimer and fibrinogen, alongside transient anticardiolipin and antiphospholipid antibody production.

Bottom line

• Mycoplasma pneumoniae infection leads to persistent colonization and highly prolonged antibody responses (IgM for months, IgG for years). It drives systemic immune activation, causing neurologic and vascular complications through anti-GalC-mediated molecular mimicry and hypercoagulability.